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A B S T R A C T
Background: Information about antimicrobial use is scarce and poorly understood among neonatal
intensive care units (NICUs) in India. In this study, we describe antimicrobial use in eight NICUs using four
point prevalence surveys (PPSs).
Methods: As part of the Global Antimicrobial Resistance, Prescribing, and Efﬁcacy in Neonates and
Children (GARPEC) study, one-day, cross-sectional, hospital-based PPSs were conducted four times
between 1 February 2016 and 28 February 2017 in eight NICUs. Using a standardized web-based
electronic data entry form, detailed data were collected for babies on antimicrobials.
Results: A total of 403 babies were admitted to NICUs across all survey days, and 208 (51.6%) were
prescribed one or more antimicrobials. Among 208 babies,155 (74.5%) were prescribed antimicrobials for
treatment of an active infection. Among 155 babies with an active infection, treatment was empiric in 109
(70.3%). Sepsis (108, 49.1%) was the most common reason for prescribing antimicrobials. Amikacin (17%)
followed by meropenem (12%) were the two most commonly prescribed antimicrobials. For community-
acquired sepsis, piperacillin-tazobactam (17.5%) was the most commonly prescribed drug. A combination
of ampicillin and gentamicin was prescribed in only two babies (5%).
Conclusions: The recommended ﬁrst-line antimicrobial agents, ampicillin and gentamicin, were rarely
prescribed in Indian NICUs for community acquired neonatal sepsis.
© 2018 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Each year, an estimated 56,624 neonates die because of sepsis
resulting from bacteria resistant to ﬁrst-line antimicrobial agents
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(http://creativecommons.org/licenses/by/4.0/).organisms are the predominant pathogens isolated from neonatal
bloodstream infections (Dharmapalan et al., 2017). Antimicrobial
resistance rates in neonatal blood stream infections in India
between 2000 and 2015 showed extremely high resistance rates to
ﬁrst-line antimicrobial agents (Dharmapalan et al., 2017). The
median ampicillin resistance rate for common Gram-negative
pathogens Klebsiella pneumoniae and Escherichia coli was 95.9% and
92.9%, respectively. Similarly, the median gentamicin resistance
rate was 75% and 55.6% for K. pneumoniae and E. coli, respectively
(Dharmapalan et al., 2017).ciety for Infectious Diseases. This is an open access article under the CC BY license
S. Gandra et al. / International Journal of Infectious Diseases 71 (2018) 20–24 21Antimicrobial resistance is a natural phenomenon but is
accelerated by the overuse and misuse of antimicrobials. Given
the high prevalence of infections by bacteria resistant to ﬁrst-line
agents, there is a need for better understanding of the current
antimicrobial prescribing practices among NICU babies in India.
However, information about antimicrobial use is scarce and comes
mainly from single center studies (Suryawanshi et al., 2015;
Chatterjee et al., 2007). In this study, we describe antimicrobial use
in eight NICUs in India using four point prevalence surveys (PPSs).
Methods
As part of the Global Antimicrobial Resistance, Prescribing, and
Efﬁcacy in Neonates and Children (GARPEC) study, one-day, cross-
sectional hospital based PPSs were conducted four times between
1 February 2016 and 28 February 2017 in eight NICUs (Gandra et al.,
2017). Four PPSs were conducted to improve the accuracy of
antimicrobial use measurement and to examine the antimicrobial
use variation at different time points. The ﬁrst PPS was conducted
between 1 February and 31 March 2016; the second between 1 May
and 30 June 2016; the third between 1 September and 31 October
2016; and the fourth between 1 December 2016 and 28 February
2017. The date of the survey was chosen as per the convenience of
the site principal investigator within the speciﬁed months. All
babies present in the NICU at 8:00 a.m. were included in the survey
and detailed data were recorded only for patients with an active
antimicrobial prescription.
Among eight participating hospitals, ﬁve hospitals enrolled into
the study at the time of initiation of the study on 1 February 2016.
Three additional hospitals were enrolled by 1 May 2016 and did not
participate in the ﬁrst round of PPS. Among the eight hospitals, two
were rural general trust hospitals, three were stand-alone private
children’s hospitals, two were private tertiary care hospitals and
one was a private mother and child-care center with inborn
neonatal services. One tertiary care hospital, two stand-alone
pediatric hospitals and the mother and child care center have
teaching services in NICUs.
We used a standardized web-based electronic data entry form
on the Research Electronic Data Capture (REDCap)1 developed for
the GARPEC project to store de-identiﬁed patient data. For patients
receiving antimicrobials (antibiotics, antifungal and antivirals,
antiparasital agents), the following data were collected: patient
sex, age, weight, ventilation status, comorbid conditions, number
of antimicrobials, antimicrobial name, dose per administration,
dose units, number of doses each day, route of administration,
reason for treatment, treatment indication (community versusTable 1
Hospital characteristics, bed occupancy and proportion of patients on antimicrobials (w
Hospital Hospital
Type
Onsite Microbiology
Laboratory
Total Number of
Beds
Bed
Occupancy (%)
Hospital A Tertiary Yes 88 71.6 
Hospital
B**
Pediatric No 16 50 
Hospital C Pediatric Yes 122 73 
Hospital
D*
Tertiary Yes 34 64.7 
Hospital E Pediatric No 106 70.8 
Hospital
F*
General &
Rural
Yes 84 79.8 
Hospital
G*
General &
Rural
No 41 100 
Hospital
H
Pediatric No 74 51.4 
All 565 71.3 
* These hospitals did not participate in the ﬁrst point prevalence survey.
** This hospital did not participate in the second and fourth prevalence survey.hospital acquired) or prophylaxis, and whether treatment was
empirical or targeted after receiving a microbiological report. We
included all diagnoses for which antimicrobials were prescribed
even when there was more than one diagnosis. Ethics approval was
obtained from the respective institutional human research ethics
committees of participating hospitals.
Categorical variables were compared with the Chi-squared test
or Fisher’s exact test, as appropriate. To investigate hospital
characteristics associated with a higher proportion of patients on
antimicrobials, we a performed multi-level mixed-effects logistic
regression model with random intercepts for each site, including
hospital type and presence of onsite diagnostic microbiology
laboratory as covariates. Statistical signiﬁcance was deﬁned as
p < 0.05. All statistical analyses were performed using STATA 14.2
(StataCorp, College Station, Texas, USA).
Results
At the eight participating hospitals, the overall bed occupancy
for all four-survey days was 71.3% and ranged from 50% to 100%
(Table 1). A total of 403 babies were hospitalized across all survey
days, and 208 babies were prescribed one or more antimicrobials
(51.6%; 95% conﬁdence interval (CI) 46.7% to 56.5%) (Table 1). The
percentage of babies on antimicrobials ranged from 18.2% to 70.7%.
Of 208 babies on antimicrobials, only one antimicrobial was
prescribed in 83 babies (39.9%), two antimicrobials were
prescribed in 111 babies (53.4%) and three or more were prescribed
in 14 babies (6.7%). There were not signiﬁcant differences among
the four PPSs at study sites (data not shown).
Onsite diagnostic microbiology services were available in four
hospitals (Table 1), and antimicrobial treatment guidelines had
been formulated in all hospitals. In the multi-level logistic
regression model, having an onsite diagnostic microbiology
laboratory was associated with lower odds of being on antimicro-
bials (adjusted odds ratio (aOR) 0.3; 95% CI 0.14 to 0.71), while
there were no signiﬁcant differences between pediatric hospitals
(reference) and rural hospitals (aOR 1.45; 95% CI 0.63 to 3.3) or
tertiary hospitals (aOR 1.75; 95% CI 0.62 to 4.96).
Of the 208 babies on antimicrobials 50% (104) were admitted to
stand-alone pediatric hospitals, followed by rural hospitals (27.9%;
58), and tertiary hospitals (22.1%; 46) (Table 2). Sixty-eight babies
(32.7%) were female and 42.3% (88) required invasive or non-
invasive ventilation support (Table 2). The majority of babies
(77.4%) had one or more co-morbidities. Of the 208 babies on
antimicrobials in NICU, 185 (88.9%) were neonates, and 23 (11%)
were older than one month. Among neonates, the medianith Wilson 95% conﬁdence interval).
Total Number of
Patients
Number of Patients on
Antimicrobials
Patients on Antimicrobials %
(95% CI)
63 42 63.7 (54.4-77.1)
8 6 75.0 (40.9-92.9)
89 31 34.8 (25.7-45.2)
22 4 18.2 (7.3-38.5)
75 42 56.0 (44.7-66.7)
67 29 43.3 (32.1-55.2)
41 29 70.7 (55.5-82.4)
38 25 65.8 (49.9-78.8)
403 208 51.6 (46.7-56.5)
Table 2
Characteristics of patients admitted to neonatal intensive care units.
Variables N (%)
Hospital type
Stand alone Pediatric 104 (50)
General Rural 58 (27.9)
Tertiary care 46 (22.1)
Female 68 (32.7)
Ventilation support
Invasive 43 (20.7)
Non-Invasive 45 (21.6)
No support 120 (57.7)
Co-morbidities
None 47 (22.6)
One 119 (57.2)
Two or more 42 (20.2)
Diagnosis*
Sepsis 108 (49.1)
Newborn Sepsis Prophylaxis for Newborn Risk Factors 33 (15.0)
Proven or probable Bacterial LRTI 28 (12.7)
Newborn Sepsis Prophylaxis for Maternal Risk Factors 21 (9.5)
Treatment: for Surgical disease 7 (3.2)
Others 23 (10.5)
Indications*
Community acquired 81 (36.8)
Hospital acquired 60 (27.2)
Prophylaxis 65 (29.5)
Unknown 14 (6.5)
Empiric vs. Targeted Therapy (n = 155)**
Empiric 109 (70.3)
Targeted 46 (29.7)
Abbreviation: LRTI, lower respiratory tract infection.
* Total can be more than 100% as one patient can have more than one diagnosis.
** Only includes antimicrobial prescriptions for active infections (prescriptions
for prophylaxis were excluded).
22 S. Gandra et al. / International Journal of Infectious Diseases 71 (2018) 20–24gestational age was 34.5 weeks (interquartile range [IQR], 31 to 38),
and median birth weight was 1737 grams (IQR, 1210 to 2710).
In 208 babies with an antimicrobial prescription, 143 (68.7%)
were prescribed for treatment of active infection, 53 (25.5%) for
prophylaxis, and in 12 (5.8%) babies for both active infection and
prophylaxis (Table 2). Among 155 babies with an active infection,
the treatment was empiric in 109 (70.3%) and targeted in 46
(29.7%). Sepsis (108, 49.1%), newborn prophylaxis for newborn risk
factors (33, 15%), and lower respiratory tract infections (LRTIs) (28,
12.7%), were the three most common reasons for prescribing
antimicrobials (Table 2 and Supplementary Table 1).
The ﬁve most common classes of antimicrobials prescribed
were aminoglycosides (26.4%), third generation cephalosporins
(14.1%), carbapenems (11.8%), piperacillin and enzyme inhibitor
combinations (11.5%) and aminopenicillins (11.5%) (Table 3).Table 3
Classes of antimicrobials prescribed by hospitals.
Overall Hospital A Hospital B Hos
Aminoglycosides 26.5 19.5 26.8 11.1
Third gen. Cephalosporins 14.1 15.9 9.8 0 
Carbapenems 11.8 19.5 14.6 22.2
Piperacillin/beta-lactamase inhibitor 11.5 2.4 29.3 11.1
Aminopenicillins 11.5 15.9 2.4 0 
Fluoroquinolones 6.9 7.3 0 11.1
Azole antifungal 4.9 8.5 2.4 0 
Glycopeptides 3.5 3.7 12.2 11.1
Polymyxins 2.3 1.2 2.4 22.2
Amphotericin B 1.7 0 0 11.1
Others* 5.2 6.2 0 0 
* Others include antivirals, glycylcycline, lincosamides, macrolides, metronidazole, oAntifungals (azoles and amphotericin B) accounted for 6.6% of
the prescriptions. Fifteen antimicrobial agents accounted for 90%
of antimicrobial use (Table 4). The ﬁve most common antimicro-
bials prescribed were amikacin (17%), meropenem (12%), piper-
acillin-tazobactam (11%), ampicillin (10%), and gentamicin (9%).
Piperacillin-tazobactam (27.7%), cefotaxime (15.7%), amikacin
(15.7%) and meropenem (7.2%) were the antimicrobials most
commonly used as monotherapy (Table 4). Ampicillin with
gentamicin (21.6%), amikacin with piperacillin-tazobactam
(10.8%), amikacin with ciproﬂoxacin (5.4%) and meropenem with
vancomycin (5.4%) were the most common antimicrobial combi-
nations used.
Among 108 babies diagnosed with sepsis (57 community-
acquired and 51 hospital-acquired), the most common antimicro-
bials prescribed were piperacillin-tazobactam (17; 15.9%), mer-
openem (7; 7.4%), combination of amikacin and piperacillin-
tazobactam (7; 6.5%), amikacin (6; 5.6%), and ceftriaxone/
cefotaxime (6; 5.6%). On reviewing empirical antimicrobial therapy
for 40 babies with community-acquired sepsis, the ﬁve most
common antimicrobial regimens prescribed were, piperacillin-
tazobactam (7; 17.5%), combination of amikacin and piperacillin-
tazobactam(5; 12.5%), combination of amikacin and ciproﬂoxacin
(5; 12.5%), amikacin alone (5; 12.5%), and combination of amikacin
and cefoperazone-sulbactam (3; 7.5%) (Supplementary Table 2).
Combination of ampicillin and gentamicin was prescribed in only
two babies (5%). Similarly, on reviewing empirical antimicrobial
therapy for 28 babies with hospital-acquired sepsis the most
common antimicrobial regimens prescribed were piperacillin-
tazobactam (5; 17.9%), ceftriaxone/cefotaxime (3; 10.7%), ﬂucona-
zole (3; 10.7%), combination of amikacin and meropenem (2; 7.1%)
and combination of amikacin and piperacillin-tazobactam (2; 7.1%)
(Supplementary Table 3).
On reviewing empirical antimicrobial therapy for 20 babies
with community-acquired LRTI, the two most common antimicro-
bial regimens prescribed were cefotaxime (4; 20%) and piperacillin
with enzyme inhibitor (3; 15%) (Supplementary Table 4). The
antimicrobial regimens prescribed for newborn prophylaxis due to
newborn risk factors include combination of ampicillin and
gentamicin (13; 39.4%), piperacillin with enzyme inhibitor (3;
9.1%) and amikacin (2; 6.1%) (Supplementary Table 5). Similarly,
the antimicrobial regimens prescribed for newborn prophylaxis
due to maternal risk factors included combination of ampicillin
and gentamicin (8; 38.1%) and amikacin (5; 23.8%).
Discussion
To our knowledge, this is the ﬁrst multi-center study describing
antimicrobial use among NICU babies in India. In this study,
approximately half (51.6%) of NICU babies received at least one
antimicrobial agent and sepsis was the most common indicationpital C Hospital D Hospital E Hospital F Hospital G Hospital H
 19.3 37.3 35.2 25.6 40
24.6 2.0 14.8 9.3 50
 7.0 7.8 7.4 11.6 0
 28.1 2.0 7.4 9.3 0
1.8 23.5 24.1 0 0
 1.8 19.6 0 14.0 0
1.8 0 7.4 9.3 0
 1.8 2.0 1.9 0 0
 0 2.0 0 7.0 0
 3.5 2.0 0 2.3 10
10.5 2.0 1.9 11.6 0
xazolidinones, penicillins, sulfonamides and trimethoprim.
Table 4
Most prescribing antimicrobials ranked by overall drug utilization 90% (DU90%).
Overall Monotherapy Part of double
combination therapy
Part of triple
combination therapy
Amikacin 17.3 15.7 19.4 9.5
Meropenem 11.8 7.2 10.8 26.2
Piperacillin-tazobactam 11.2 27.7 6.3 4.8
Ampicillin 10.1 1.2 14.0 7.1
Gentamicin 9.2 3.6 13.1 0
Cefotaxime 5.8 15.7 3.2 0
Fluconazole 4.9 2.4 4.1 14.3
Ciproﬂoxacin 3.8 4.8 4.1 0
Vancomycin 3.5 1.2 4.1 4.8
Ceftriaxone 2.6 4.8 2.3 0
Colistin 2.3 0 2.7 4.8
Levoﬂoxacin 2.0 2.4 2.3 0
Cefoperazone Sulbactam 3.2 0 4.5 2.4
Amphotericin B/Amphotericin B liposomal 1.7 2.4 1.4 2.4
Cefoperazone 1.4 1.2 1.4 2.4
S. Gandra et al. / International Journal of Infectious Diseases 71 (2018) 20–24 23for prescribing antimicrobials. Amikacin was the most commonly
prescribed antimicrobial agent followed by meropenem. Piper-
acillin-tazobactam was the most frequently prescribed empirical
antimicrobial agent for community-acquired sepsis.
In the global Antibiotic Resistance and Prescribing in European
Children (ARPEC) PPS study conducted in 2012, involving 226
hospitals from 41 countries, the overall percentage of neonates in
NICU on antimicrobials was 30.3%, which was much lower than the
51.6% in our study (Versporten et al., 2016). Similar to global ARPEC
study, sepsis was the most common reason for prescribing
antimicrobials and aminoglycosides were the most commonly
prescribed class of antimicrobials. However, the most commonly
prescribed aminoglycoside was gentamicin, while in our study it
was amikacin. Similar ﬁndings were observed in a three-year
observational study involving two NICUs in Central India, where
amikacin was the most commonly prescribed antimicrobial and
comprised 18% of antimicrobial prescriptions (Hauge et al., 2017).
The preference of amikacin over gentamicin might have been
motivated by the susceptibility proﬁle of Gram-negative pathogens
in India. A recent review of antimicrobial resistance among
bloodstream infections in neonates and children showed that the
median gentamicin resistance rates were 75% and 55.6% for K.
pneumoniae and E. coli respectively whereas median amikacin
resistance rates were 41% and 22.4%, respectively (Dharmapalan
et al., 2017).
The World Health Organization (WHO) and the Indian National
Center for Disease Control (NCDC) recommend the combination of
ampicillin and gentamicin as ﬁrst-line empiric therapy for
community acquired neonatal sepsis or pneumonia (National
Center for Disease Control, 2016; Organization WH, 2012).
However, we found that this combination was rarely used in the
hospitals that participated in our study. Only two out of 40 babies
with community-acquired sepsis and none of the 20 babies with
community-acquired pneumonia were prescribed ampicillin and
gentamicin. Instead, piperacillin-tazobactam or amikacin alone or
combination of piperacillin-tazobactam and amikacin were
commonly prescribed for community-acquired sepsis. For com-
munity-acquired pneumonia, cefotaxime as single agent and
piperacillin-tazobactam alone were commonly prescribed. Ampi-
cillin and gentamicin combination was only frequently prescribed
for newborn prophylaxis due to neonatal or maternal risk factors.
These antimicrobial prescribing practices might have been
inﬂuenced by factors such as local antimicrobial susceptibility
proﬁle, availability and utilization of diagnostic microbiology
services, severity of illness, and implementation of antimicrobial
treatment polices. With the reported median ampicillin resistance
rate more than 90% and median gentamicin resistance rate of morethan 55% for K. pneumoniae and E. coli, the use of second line broad-
spectrum agents may seem appropriate. However, with the high
level of empiric therapy observed (71%), there could be greater
inappropriate therapy. This is supported by a recent study in a
single NICU, where implementation of antimicrobial policy based
on microbiology information for neonatal sepsis in one of the
participating hospitals (Hospital F) resulted in increased use of
ﬁrst-line agents and reduced use of third generation cephalospor-
ins without effecting patient outcomes (Jinka et al., 2017). This
highlights the importance of facility-based treatment guidelines,
which are developed, based on the local microbiology data.
In our study, we observed that meropenem was the second
most common antimicrobial agent prescribed after amikacin. It
was mainly prescribed as empiric therapy for hospital-acquired
infections as single agent or in combination with other agents. The
use of meropenem may be indicated due to high prevalence of
third generation cephalosporin resistant and extended spectrum
beta-lactamase (ESBL) producing Klebsiella species and E. coli. This
is evident by review of antimicrobial resistance rates among
bloodstream infections in neonates between 2000 and 2015
(Dharmapalan et al., 2017). The median ceftriaxone resistance for
Klebsiella species and E. coli was 65% and 50% respectively.
However, with increased meropenem selection pressure, caraba-
penem resistant Klebsiella species have emerged and are increas-
ingly encountered in Indian NICUs (Jinka et al., 2017; Investigators
of the Delhi Neonatal Infection Study (DeNIS) Collaboration, 2016).
There is an urgent need for carbapenem sparing agents to treat
infections caused by ESBL-producing organisms to decrease the
carbapenem selection pressure. Although, several studies suggest
that piperacillin-tazobactam could be effective for infections by
ESBL Enterobacteriaceae (Yoon et al., 2017; Gudiol et al., 2017),
some studies indicate better survival rates with carbapenems
(Tamma et al., 2015). Novel beta-lactam/beta-lactamase inhibitor
combinations such as ceftazidime-avibactam and ceftolozane-
tazobactam were non-inferior to carbapenems in treating invasive
infections due to ESBL producing organism in randomized clinical
trials (Wagenlehner et al., 2016; Popejoy et al., 2016). However,
safety and efﬁcacy data in neonates are not yet available.
Meanwhile, implementing effective infection control practices is
paramount to prevent the spread of these organisms in NICUs.
One interesting ﬁnding we observed in the study was that the
proportion of babies on antimicrobials was lower in hospitals with
onsite diagnostic microbiology laboratory, in spite of having
antimicrobial treatment guidelines in all eight NICUs. This
probably can be explained by the fact the utilization of microbio-
logical culture results helped in de-escalating or stopping the
empiric antimicrobial therapy early, especially among patients
24 S. Gandra et al. / International Journal of Infectious Diseases 71 (2018) 20–24with possible and probable sepsis, and thus reduce the number of
patients on antimicrobials at any given time in a ward.
The study has several strengths. First, the repeated PPSs in the
eight NICUs increased the robustness of our estimates of
antimicrobial prescription among NICU babies. Second, we were
able to capture antimicrobial prescribing practices in different
types of hospitals as the eight participating hospitals represented
diverse settings that are commonly seen in India. Four hospitals
were stand-alone children hospitals in urban areas, two were part
of a rural general hospital, and two were part of large tertiary care
referral centers. Third, we examined the variation of antimicrobial
use at different times of the year. Interestingly, the percentages of
children on antimicrobials were not signiﬁcantly different among
PPSs and, thus, we did not observe any temporal variation in
antimicrobial prescribing. However, the study also has several
limitations. First, appropriateness of antimicrobial prescribing was
not assessed, as we did not collect data on the duration of therapy,
or the microbiology and antimicrobial susceptibility results.
Second, although we included hospitals with different character-
istics, we did not include hospitals from the public sector nor from
all regions of India. Thus, our results may not be generalizable to all
healthcare settings and geographic regions of the country.
However, private sector accounts for more than 60% of healthcare
services in India (Hauge et al., 2017). Third, as the date of the survey
was chosen as per the convenience of the site principal investigator
within the speciﬁed months and physicians knew that their
antimicrobial prescriptions were being studied, the results might
have been affected by a Hawthorne effect.
In conclusion, our study reports that half of NICU babies were
on at least one antimicrobial agent and more than 70% of treatment
was empiric. The recommended ﬁrst-line antimicrobial agents,
ampicillin and gentamicin were rarely prescribed in Indian NICUs
for community acquired neonatal sepsis and pneumonia. Amikacin
and other broad-spectrum agents like piperacillin-tazobactam and
third generation cephalosporins were commonly used as empiric
choices for community-acquired neonatal sepsis and pneumonia.
Although, high resistance rates reported to ﬁrst-line agents may
support the use of second-line broad-spectrum agents, there is
evidence that implementation of facility based treatment guide-
lines by incorporating diagnostic microbiological information
could reduce the amount of broad-spectrum antimicrobials use
and increase the use of ﬁrst-line agents in Indian NICUs.
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